Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter

International Journal of Biochemistry and Molecular Biology

Volumn 3, Issue 2, 2012, Pages 179-197

  Cheng, Qiuying ^a   Ling, Xiang ^a   Haller, Andrew ^a   Nakahara, Takahito ^b   Yamanaka, Kentaro ^b   Kita, Aya ^b   Koutoku, Hiroshi ^b   Takeuchi, Masahiro ^b   Brattain, Michael G ^a,c   Li Dr , Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ASTELLAS PHARMA INC   (Japan)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer cells; The survivin promoter; YM155

Indexed keywords

LUCIFERASE; OLIGONUCLEOTIDE; SEPANTRONIUM BROMIDE; SURVIVIN; TRANSCRIPTION FACTOR SP1;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MUTATION; PROMOTER REGION; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION;

EID: 84862502289     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Deveraux QL and Reed JC. IAP family proteins-- suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
2. Liston P, Fong WG and Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003; 22: 8568-8580.
3. Salvesen GS and Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-410.
4. Li F. Survivin Study: What is the next wave? J Cell Physiol 2003; 197: 8-29.
5. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003; 5: 447-452.
6. Wheatley SP and McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005; 247: 35-88.
7. Li F and Ling X. Survivin Study: An update of "What is the next wave?" J Cell Physiol 2006; 208: 476-486.
8. Lechler P, Wu X, Bernhardt W, Campean V, Gastiger S, Hackenbeck T, Klanke B, Weidemann A, Warnecke C, Amann K, Engehausen D, Willam C, Eckardt KU, Rodel F and Wiesener MS. The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney. Am J Pathol 2007; 171: 1483-1498.
9. Li F and Brattain MG. Role of the Survivin Gene in Pathophysiology. Am J Pathol 2006; 169: 1-11.
10. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E and Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci USA 2006; 103: 6332-6337.
11. Iurlaro M, Demontis F, Corada M, Zanetta L, Drake C, Gariboldi M, Peiro S, Cano A, Navarro P, Cattelino A, Tognin S, Marchisio PC and Dejana E. VE-Cadherin Expression and Clustering Maintain Low Levels of Survivin in Endothelial Cells. Am J Pathol 2004; 165: 181-189.
12. Conway EM, Zwerts F, Van Eygen V, DeVriese A, Nagai N, Luo W and Collen D. Survivindependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced upregulation. Am J Pathol 2003; 163: 935-946.
13. Byun SJ, Choi KS, Park SH, Cho NW, Hyun Yoo C, Yun KJ, Koh YJ, Koh GY, So BJ and Yoon KH. Cartilage oligometric matrix proteinangiopoietin- 1 promotes revascularization through increased survivin expression in dermal endothelial cells of skin grafts in mice. Am J Pathol 2007; 171: 1682-1690.
14. Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC and Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008; 173: 575-585.
15. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-216.
16. Ling X, He X, Apontes P, Cao F, Azrak RG and Li F. Enhancing effectiveness of the MDRsensitive compound T138067 using advanced treatment with negative modulators of the drug -resistant protein survivin. Am J Transl Res 2009; 1: 393-405.
17. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M and Sasamata M. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2010; 102: 614-621.
18. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M and Sasamata M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
19. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K and Nakagawa K. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008; 14: 6496-6504.
20. Minematsu T, Iwai M, Umehara KI, Usui T and Kamimura H. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)-, and OCT2 (SLC22A2)-mediated transport of YM155 monobromide, a novel survivin suppressant. Drug Metab Dispos 2010; 38: 1-4.
21. Minematsu T, Iwai M, Sugimoto K, Shirai N, Nakahara T, Usui T and Kamimura H. Carrier- Mediated Uptake of YM155 Monobromide, 1-(2 -Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2- ylmethyl)-4,9-dihydro-1 H-naphtho[2,3-d] imidazolium Bromide, a Novel Small-molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells. Drug Metab Dispos 2009; 37: 619-628.
22. Minematsu T, Felder L, Oppeneer T, Sakazume M, Oikawa K, Hashimoto T, Usui T and Kamimura H. Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma. Biomed Chromatogr 2008; 22: 763-769.
23. Iwai M, Minematsu T, Narikawa S, Usui T and Kamimura H. Involvement of human organic cation transporter 1 in the hepatic uptake of 1- (2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin- 2-ylmethyl)-4,9-dihydro-1 H-naphtho[2,3-d] imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos 2009; 37: 1856-1863.
24. Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, Koutoku H, Sasamata M, Hatashita E, Yamada Y, Kuwata K, Fukuoka M and Nakagawa K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer 2010; 103: 36-42.
25. Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N and Sasamata M. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 2011; 35: 787-792.
26. Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H and Sasamata M. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol 2011; 39: 569-575.
27. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A and Antonia S. Phase I and Pharmacokinetic Study of YM155, a Small- Molecule Inhibitor of Survivin. J Clin Oncol 2008; 26: 5198-5203.
28. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, Saito T, Masuda N, Watanabe H, Taguchi T, Kakihara T, Aoyama Y, Hashimoto Y and Nakagawa K. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3872-3880.
29. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E and Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2009; 29: 161-166.
30. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27: 4481-4486.
31. NCI Drug Dictionary: Survivin inhibitor YM155 clinical trial: NCI (http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=476771)
32. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A and de Bono JS. A phase II study of YM155, a novel smallmolecule suppressor of survivin, in castrationresistant taxane-pretreated prostate cancer. Ann Oncol 2012; 23: 968-973.
33. Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, Kaneko N and Sasamata M. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 2011; 17: 5423-5431.
34. Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H and Sasamata M. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 2011; 22: 454-462.
35. Li F and Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344: 305-311.
36. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
37. Ling X, Bernacki RJ, Brattain MG and Li F. Induction of survivin expression by taxol (paclitaxel) is an early event which is independent on taxol-mediated G2/M arrest. J Biol Chem 2004; 279: 15196-15203.
38. Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T and Li F. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence selective DNAbinding antitumor agent, hedamycin: evidence of survivin downregulation associated with drug sensitivity. J Biol Chem 2005; 280: 9745-9751.
39. Wu J, Apontes P, Song L, Liang P, Yang L and Li F. Molecular mechanism of upregulation of survivin transcription by the AT-rich DNAbinding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Res 2007; 35: 2390-2402.
40. Ling X, Cheng Q, Black JD and Li F. Forced Expression of Survivin-2B Abrogates Mitotic Cells and Induces Mitochondria-dependent Apoptosis by Blockade of Tubulin Polymerization and Modulation of Bcl-2, Bax, and Survivin. J Biol Chem 2007; 282: 27204-27214.
41. Lo K, Landau NR and Smale ST. LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. Mol Cell Biol 1991; 11: 5229-5243.
42. Spaulding B, Pan D, Ghadersohi A, Nielsen G, Jensen S, Gellert F, Ling X, Zhang M, Black A and Li F. Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues. Histopathology 2006; 49: 622-633.
43. Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-1127.
44. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-466.
45. Reed JC and Reed SI. Survivin' cell-separation anxiety. Nat Cell Biol 1999; 1: E199-200.
46. Skoufias DA, Mollinari C, Lacroix FB and Margolis RL. Human survivin is a kinetochoreassociated passenger protein. J Cell Biol 2000; 151: 1575-1582.
47. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL and Choo KH. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000; 10: 1319-1328.
48. Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L and Brattain MG. Differential regulation of survivin expression and apoptosis by vitamin D(3) compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 2005; 24: 1385-1395.
49. Zhang M, Yang J and Li F. Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res 2006; 25: 391-402.
50. Li F, Cheng Q, Ling X, Stablewski A, Tang L, Foster BA, Johnson CS, Rustum YM and Porter CW. Generation of a Novel Transgenic Mouse Model for Bioluminescent Monitoring of Survivin Gene Activity in Vivo at Various Pathophysiological Processes. Survivin Expression Overlaps with Stem Cell Markers. Am J Pathol 2010; 176: 1629-1638.
51. Li F, Baykal D, Horaist C, Yan CN, Carr BN, Rao GN and Runge MS. Cloning and identification of regulatory sequences of the human thrombin receptor gene. J Biol Chem 1996; 271: 26320-26328.
52. Li F and Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999; 59: 3143-3151.
53. Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y and Yan B. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 2006; 25: 3296-3306.
54. Xu R, Zhang P, Huang J, Ge S, Lu J and Qian G. Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 2007; 356: 286-292.
55. Chun JY, Hu Y, Pinder E, Wu J, Li F and Gao AC. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 2007; 6: 2572-2580.